Palotic 0.075 mg/1.5 ml (IV Injection)
Medicine Details
| Category | Details |
|---|---|
| Generic | Palonosetron |
| Company | Popular pharmaceuticals ltd |
| Also available as |
Title
- Palotic
Categories
- Medicine
- Anti-emetic drugs
Description
Palotic is indicated for acute and delayed nausea and vomiting, uncontrolled nausea and vomiting, chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), post-operative & post-discharge nausea and vomiting (PONV & PDNV). It is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Palonosetron exhibits linear dose-proportional pharmacokinetics and has a longer half-life (40 hours) with a greater 5-HT3 receptor binding affinity. The usual dosage for adults is 0.5 mg daily for tablets and a single IV dose of 0.075 mg should be administered over 10 seconds. Interaction studies have shown that Palotic has no significant pharmacokinetic interactions with other medications. It is contraindicated in patients known to have hypersensitivity to the drug or any of its components. The most common adverse reactions are headaches and constipation. It is pregnancy category 'B' and it is not known whether Palonosetron is excreted in breast milk. No dosage adjustment is recommended in elderly patients, children, and patients with impaired renal and hepatic function. Overdose should be managed with supportive care. Store in a cool & dry place, protected from light.
Dosage & Administration
- Adult tablet dosage: 0.5 mg daily
- Adult IV dosage: A single IV dose of 0.075 mg should be administered over 10 seconds
- Children dosage: (1 month to 17 years): A single IV dose at 20 mcg/kg body weight with a maximum dose of 1.5 mg.
Pharmacology
- Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity
- Chemotherapeutic agents release serotonin from the enterochromaffin cells, triggering vomiting reflex
- Palonosetron works by blocking the actions of Serotonin at 5-HT3 receptor
- Exhibits linear dose-proportional pharmacokinetics
- Metabolized via kidney and liver CYP2D6, CYP3A4, and CYP1A2 isoenzymes
- Approximately 40% of the drug is metabolized via kidney, 50% by liver
Interaction
- Safe administration with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents
- No inhibition of the antitumor activity of specific drugs
Contraindications
- Palonosetron is contraindicated in patients known to have hypersensitivity to the drug or any of its components
Side Effects
- The most common adverse reactions are headaches and constipation
Pregnancy & Lactation
- Pregnancy category 'B'
- Not known whether Palonosetron is excreted in breast milk
Use in Special Populations
- No dosage adjustment is recommended in elderly patients >65 years of age
- No dosage adjustment is recommended in patients with renal and hepatic dysfunction
Overdose Effects
- There is no known antidote to Palotic. Overdose should be managed with supportive care
Therapeutic Class
- Anti-emetic drugs
Storage Conditions
- Store in a cool & dry place, protected from light